New results for insulin degludec in type 1 diabetes

First published November 2016, updated March 2022   Results from a study comparing the pharmacodynamics of insulin degludec (Tresiba) with insulin glargine U300 in people with type 1 diabetes were presented at the 16th Annual Diabetes Technology Meeting in Bethesda, US. Treatment with insulin degludec (0.4 U/kg) resulted in lower day-to-day and within-day variability in glucose-lowering effect, compared with insulin glargine U300 (0.4 U/kg). The study showed that the day-to-day variability was approximately four times lower with insulin degludec than with insulin glargine U300. Within-day variability was approximately 40% lower with insulin degludec, with the glucose-lowering effect being more evenly